These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37988466)
1. A Novel mechanism of herbicide action through disruption of pyrimidine biosynthesis. Kang IH; Emptage RP; Kim SI; Gutteridge S Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2313197120. PubMed ID: 37988466 [TBL] [Abstract][Full Text] [Related]
2. Bioisosteric Tactics in the Discovery of Tetflupyrolimet: A New Mode-of-Action Herbicide. Selby TP; Satterfield AD; Puri A; Stevenson TM; Travis DA; Campbell MJ; Taggi AE; Hughes KA; Bereznak J J Agric Food Chem; 2023 Nov; 71(47):18197-18204. PubMed ID: 37285594 [TBL] [Abstract][Full Text] [Related]
3. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Vyas VK; Ghate M Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807 [TBL] [Abstract][Full Text] [Related]
4. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay. Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475 [TBL] [Abstract][Full Text] [Related]
5. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode. Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527 [TBL] [Abstract][Full Text] [Related]
7. Identification of 3,4-Dihydro-2 Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290 [No Abstract] [Full Text] [Related]
8. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022). Gehlot P; Vyas VK Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210 [TBL] [Abstract][Full Text] [Related]
10. Protein-lipid interactions of human dihydroorotate dehydrogenase and three mutants associated with Miller syndrome. Orozco Rodriguez JM; Wacklin-Knecht H; Knecht W Nucleosides Nucleotides Nucleic Acids; 2022; 41(12):1337-1358. PubMed ID: 35184687 [TBL] [Abstract][Full Text] [Related]
11. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors. Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381 [TBL] [Abstract][Full Text] [Related]
12. Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor. Alberti M; Sainas S; Ronchi E; Lolli ML; Boschi D; Rizzi M; Ferraris DM; Miggiano R FEBS Lett; 2023 Aug; 597(16):2119-2132. PubMed ID: 37278160 [TBL] [Abstract][Full Text] [Related]
13. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo. Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345 [TBL] [Abstract][Full Text] [Related]
14. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells. Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894 [TBL] [Abstract][Full Text] [Related]
16. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor. Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990 [TBL] [Abstract][Full Text] [Related]
19. Dual binding mode of a novel series of DHODH inhibitors. Baumgartner R; Walloschek M; Kralik M; Gotschlich A; Tasler S; Mies J; Leban J J Med Chem; 2006 Feb; 49(4):1239-47. PubMed ID: 16480261 [TBL] [Abstract][Full Text] [Related]
20. Protein production, kinetic and biophysical characterization of three human dihydroorotate dehydrogenase mutants associated with Miller syndrome. Orozco Rodriguez JM; Krupinska E; Wacklin-Knecht H; Knecht W Nucleosides Nucleotides Nucleic Acids; 2022; 41(12):1318-1336. PubMed ID: 35094635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]